ReviewMolecular biology reports2026
The role of 2'-5'-oligoadenylate synthetase (OAS) proteins in HIV infection: innate antiviral immunity, viral persistence, and therapeutic opportunities.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus type 1 (HIV-1) establishes persistent infection despite robust innate immune responses and effective antiretroviral therapy, highlighting the importance of host antiviral mechanisms in regulating viral replication and persistence. Among interferon-stimulated genes, 2'-5'-oligoadenylate synthetase 1 (OAS1) is a key antiviral effector that senses viral double-stranded RNA and activates the OAS-RNase L pathway. Beyond its canonical antiviral activity, emerging evidence implicates OAS1 in immune regulation, viral latency, neuroinflammation, and retroviral disease progression. This review examines the genomic organization, structural diversity, isoform-specific functions, genetic variation, and interferon-mediated regulation of the OAS protein family, emphasizing OAS1 in HIV infection. Experimental and clinical studies indicate that type I and type III interferons induce OAS1 in macrophages, dendritic cells, epithelial and endothelial cells, microglia, and lymphocytes, contributing to HIV restriction through RNase L activation and enhanced innate antiviral responses. OAS signalling may also support mucosal antiviral defence, regulate viral burden and chronic immune activation, influence interferon responsiveness during combination antiretroviral therapy, and contribute to central nervous system protection. Conversely, dysregulated OAS1 expression has been associated with HIV-associated neurocognitive disorders. Genetic polymorphisms and alternative splicing generate functional diversity in OAS1, potentially influencing antiviral activity, individual susceptibility, and clinical outcomes. Collectively, available evidence positions OAS1 as a multifunctional antiviral and immunoregulatory component of host defence that may influence multiple aspects of HIV pathogenesis. Further investigation into OAS1 activation, genetic variation, isoform-specific functions, and immune modulation may facilitate biomarker discovery and support the development of host-directed therapeutic strategies against persistent retroviral infections.
Indexed as
Identifiers
42911453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.